NYSE: MRKMerck & Co Inc Stock Forecast, Predictions & Price Target
Analyst price target for MRK
Based on 11 analysts offering 12 month price targets for Merck & Co Inc.
Min Forecast
$88.00+12.43%
Avg Forecast
$94.18+20.33%
Max Forecast
$107.00+36.71%
Should I buy or sell MRK stock?
Strong Buy
Strong Buy
9 analysts 69.23%
Buy
0 analysts 0.00%
Hold
4 analysts 30.77%
Sell
0 analysts 0.00%
Strong Sell
0 analysts 0.00%
Forecast return on equity
Is MRK forecast to generate an efficient return?
Company
47.57%
Industry
55.96%
Market
-1.56%
MRK's Return on Equity is forecast to be high in 4 years (47.57%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is MRK forecast to generate an efficient return on assets?
Company
14.51%
Industry
15.11%
Market
11.47%
MRK is forecast to generate lower Return on Assets (14.51%) than the US Drug Manufacturers - General industry average (15.11%)
Forecast
MRK earnings per share forecast
What is MRK's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$5.70+37.91%
Avg 2 year Forecast
$5.98+44.86%
Avg 3 year Forecast
$6.58+59.32%
MRK's earnings are forecast to grow at a rate of 16.21% per year, which is not exceptional
Forecast
MRK revenue forecast
What is MRK's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$47.9B+1.50%
Avg 2 year Forecast
$50.9B+7.94%
Avg 3 year Forecast
$53.9B+14.13%
MRK's revenue is forecast to grow at a rate of 4.52% per year, which is not exceptional
Forecast
MRK earnings growth forecast
How is MRK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
16.21%
Industry
20.03%
Market
14.71%
MRK's earnings are forecast to grow slower (16.21% per year) than the US Drug Manufacturers - General industry average (20.03%)
Forecast
MRK's earnings are forecast to grow faster (16.21% per year) than the US market average (14.71%)
Forecast
MRK revenue growth forecast
How is MRK forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
4.52%
Industry
6.43%
Market
5.62%
MRK's revenues are forecast to grow slower (4.52% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
MRK's revenues are forecast to grow slower (4.52% per year) than the US market average (5.62%)
Forecast
Merck & Stock Forecast FAQ
Is Merck & Stock a good buy in 2020, according to Wall Street analysts?
The consensus among 13 Wall Street analysts covering (NYSE: MRK) stock is to Strong Buy MRK stock.
Out of 13 analysts, 9 (69.23%) are recommending MRK as a Strong Buy, 0 (0.00%) are recommending MRK as a Buy, 4 (30.77%) are recommending MRK as a Hold, 0 (0.00%) are recommending MRK as a Sell, and 0 (0.00%) are recommending MRK as a Strong Sell.
What is MRK's Price Target?
According to 11 Wall Street analysts that have issued a 1 year MRK price target, the average MRK price target is $94.18, with the highest MRK stock price forecast at $107.00 and the lowest MRK stock price forecast at $88.00.
On average, Wall Street analysts predict that Merck &'s share price could reach $94.18 by Oct 16, 2021. The average Merck & stock price prediction forecasts a potential upside of 20.33% from the current MRK share price of $78.27.
What is MRK's earnings growth forecast for 2020-2022?
(NYSE: MRK) Merck &'s forecast annual earnings growth rate of 16.21% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 20.03%, and while it is forecast to beat the US market's average forecast earnings growth rate of 14.71%.
Merck &'s earnings in 2020 is $10,478,000,000.On average, 7 Wall Street analysts forecast MRK's earnings for 2020 to be $14,376,523,154, with the lowest MRK earnings forecast at $14,210,689,705, and the highest MRK earnings forecast at $14,589,304,884. On average, 7 Wall Street analysts forecast MRK's earnings for 2021 to be $15,101,445,016, with the lowest MRK earnings forecast at $12,317,613,812, and the highest MRK earnings forecast at $16,532,862,801.
In 2022, MRK is forecast to generate $16,608,585,837 in earnings, with the lowest earnings forecast at $13,049,603,157 and the highest earnings forecast at $19,082,205,004.
What is MRK's revenue growth forecast for 2020-2022?
(NYSE: MRK) Merck &'s forecast annual revenue growth rate of 4.52% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.62%.
Merck &'s revenue in 2020 is $47,194,000,000.On average, 3 Wall Street analysts forecast MRK's revenue for 2020 to be $120,908,460,369,794, with the lowest MRK revenue forecast at $119,649,968,756,973, and the highest MRK revenue forecast at $121,600,897,049,521. On average, 3 Wall Street analysts forecast MRK's revenue for 2021 to be $128,580,279,156,350, with the lowest MRK revenue forecast at $120,745,428,673,867, and the highest MRK revenue forecast at $135,020,811,092,722.
In 2022, MRK is forecast to generate $135,949,940,313,433 in revenue, with the lowest revenue forecast at $123,670,861,954,236 and the highest revenue forecast at $144,918,442,887,931.
What is MRK's Earnings Per Share (EPS) forecast for 2020-2022?
(NYSE: MRK) Merck &'s current Earnings Per Share (EPS) is $4.13. On average, analysts forecast that MRK's EPS will be $5.70 for 2020, with the lowest EPS forecast at $5.63, and the highest EPS forecast at $5.78. On average, analysts forecast that MRK's EPS will be $5.98 for 2021, with the lowest EPS forecast at $4.88, and the highest EPS forecast at $6.55. In 2022, MRK's EPS is forecast to hit $6.58 (min: $5.17, max: $7.56).
What is MRK's forecast return on equity (ROE) for 2020-2023?
(NYSE: MRK) forecast ROE is 47.57%, which is considered strong.
What is MRK's forecast return on assets (ROA) for 2020-2023?
(NYSE: MRK) forecast ROA is 14.51%, which is lower than the forecast US Drug Manufacturers - General industry average of 15.11%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
